The recently unveiled conjugate DS3610a is to start phase 1.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
Duality takes its Adam9-targeting conjugate into the clinic.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
